U.S. markets closed

Ultragenyx Pharmaceutical Inc. (RARE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
95.49+0.57 (+0.60%)
At close: 4:00PM EDT
95.49 0.00 (0.00%)
After hours: 04:05PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Hammer

Hammer

Previous Close94.92
Open94.96
Bid94.82 x 900
Ask106.90 x 900
Day's Range93.56 - 96.75
52 Week Range72.43 - 179.65
Volume959,649
Avg. Volume461,087
Market Cap6.565B
Beta (5Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-3.23
Earnings DateJul 28, 2021 - Aug 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est153.44
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • New Strong Sell Stocks for June 18th
    Zacks

    New Strong Sell Stocks for June 18th

    OEG, EAF, RARE, EGRX, and TELA have been added to the Zacks Rank #5 (Strong Sell) List on June 18, 2021

  • GeneTx and Ultragenyx Receive Approval from U.K. Regulatory Agency to Begin Clinical Study of GTX-102 for the Treatment of Angelman Syndrome
    GlobeNewswire

    GeneTx and Ultragenyx Receive Approval from U.K. Regulatory Agency to Begin Clinical Study of GTX-102 for the Treatment of Angelman Syndrome

    Patient enrollment to begin in early second half of 2021 in U.K. and Canada GeneTx to submit revised protocol to U.S. Food and Drug Administration seeking study resumption in U.S. following May meeting SARASOTA, Fla. and NOVATO, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of intrathecally administered GTX-102, an investigational treatment for Angelman syndrome, today announced that

  • Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conference
    GlobeNewswire

    Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conference

    NOVATO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Goldman Sachs 42nd Annual Healthcare Conference on Thursday, June 10, 2021 at 3:00 PM ET. The live and archived webcast of the present